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Abstract
Background: Volatile sedation in the intensive care unit (ICU) may reduce the number of adverse events and improve patient
outcomes compared with intravenous (IV) sedation. We performed a systematic review and meta-analysis comparing the effects of
volatile and IV sedation in adult ICU patients.
Methods:We searched the PubMed, Embase, Cochrane Central Register, andWeb of Science databases for all randomized trials
comparing volatile sedation using an anesthetic-conserving device (ACD) with IV sedation in terms of awakening and extubation
times, lengths of ICU and hospital stay, and pharmacologic end-organ effects.
Results:Thirteen trials with a total of 1027 patients were included. Volatile sedation (sevoﬂurane or isoﬂurane) administered through
an ACD shortened the awakening time [mean difference (MD),80.0minutes; 95% conﬁdence intervals (95%CIs),134.5 to25.6;
P= .004] and extubation time (MD,196.0minutes; 95% CIs,305.2 to86.8; P< .001) compared with IV sedation (midazolam or
propofol). No differences in the lengths of ICU and hospital stay were noted between the 2 groups. In the analysis of cardiac effects of
sedation from 5 studies, patients who received volatile sedation showed lower serum troponin levels 6hours after ICU admission than
patients who received IV sedation (P< .05). The effect size of troponin was largest between 12 and 24hours after ICU admission (MD,
0.27mg/L; 95% CIs, 0.44 to 0.09; P= .003).
Conclusion:Compared with IV sedation, volatile sedation administered through an ACD in the ICU shortened the awakening and
extubation times. Considering the difference in serum troponin levels between both arms, volatile anesthetics might have a
myocardial protective effect after cardiac surgery even at a subanesthetic dose. Because the included studies used small sample
sizes with high heterogeneity, further large, high-quality prospective clinical trials are needed to conﬁrm our ﬁndings.
Abbreviations: ACD = anesthetic conserving device, CI = conﬁdence interval, ICU = intensive care unit, IV = intravenous, LOS =
length of stay, MD =mean difference, MV =mechanical ventilation, NT-proBNP = serum N-terminal prohormone of brain natriuretic
peptide, OR= odds ratio, PICOS= the Patient, Intervention, Comparator, Outcomes, and Study, PONV= postoperative nausea and
vomiting, PRISMA = the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, RCT = randomized controlled trial.
Keywords: anesthetics, critical care, inhalation, meta-analysis, sedation1. Introduction
Suboptimal sedation in critically ill patients is associated with
adverse events, high costs, and increases in morbidity and
mortality.[1–3] The current sedation guidelines, which are
updated periodically, are based on intravenous (IV) agents.[2]Editor: Chien-Kun Ting.
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1However, the updated sedation practices with IV agents are
problematic due to adverse effects such as accumulation,
tolerance, withdrawal, delirium, and hemodynamic instability.[4–9]
Volatile anesthetic agents used in general anesthesia have also
been used as sedatives due to favorable pharmacokinetics such as
rapid elimination via pulmonary exhalation, limited hepatic
metabolism, and no accumulation.[10–12] Moreover, the periop-
erative organ protective effects of volatile anesthetic agents,
especially on the heart, have been conﬁrmed through the
mechanisms of ischemic pre- and post-conditioning.[13–17]
Nevertheless, the use of volatile sedation in the intensive care
unit (ICU) has been limited due to intensivists’ lack of familiarity
with these agents, emergence agitation, postoperative nausea and
vomiting (PONV), and nephrotoxicity from inorganic ﬂuo-
ride.[18–22] Most importantly, volatile sedation in the ICU has
been limited by technical problems, including the wasting of
volatile agents by high-ﬂow ICU ventilators and atmospheric
contamination by open ventilator circuits.[23]
Volatile sedation in the ICU is becoming increasingly popular
due to fewer technical problems since the development of
anesthetic reﬂectors, such as AnaConDa (SEDANA Medical,
Uppsala, Sweden) and Mirus (Pall Medical, Dreieich, Germany),
which reduce volatile agent wasting.[24,25] Once these anesthetic
reﬂectors were commercially available, several small randomized
controlled trials were published comparing the effects of
volatile and conventional IV sedative agents in the ICU.[26–38]
Kim et al. Medicine (2017) 96:49 MedicineTherefore, we performed a systematic review and meta-analysis
of randomized controlled trials (RCTs) using these new
anesthetic reﬂectors (AnaConDa and Mirus) to evaluate whether
volatile sedation is associated with improved outcomes compared
with IV sedation in adult ICU patients.2. Materials and methods
2.1. Literature search
This study was performed according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines for systematic reviews and meta-analyses of RCTs.[39]
This study did not require ethical approval because it was an
analysis of previously published studies. Two independent
reviewers (JMK and HYK) separately searched the PubMed,
Embase, Cochrane Central Register, and Web of Science of
Controlled Trials databases for all studies, regardless of
language, published before May 31, 2017. The search terms
used were: (“sevoﬂurane”OR “isoﬂurane”OR “desﬂurane”OR
“anesthetic conserving device” OR “AnaConDa” OR “Mirus”)
AND ‘sedation” AND (“critical care” OR “intensive care”).
Additional studies were identiﬁed by manually searching the
references of the original studies.2.2. Study selection
We included RCTs and quasi-RCTs of patients who underwent
sedation in the ICU. The inclusion criteria, based on the Patient,
Intervention, Comparator, Outcomes, and Study (PICOS) design
criteria, were as follows: patient: adult patients (≥18 years) who
underwent sedation in the ICU; intervention: patients sedated
with volatile sedatives (sevoﬂurane, isoﬂurane, or desﬂurane) via
an AnaConDa or Mirus reﬂector; comparator: patients sedated
with IV sedatives; at least 1 primary outcome [awakening time,
extubation time, length of stay (LOS) in the ICU, or LOS in the
hospital] or secondary outcomes (myocardial effects, renal
effects, incidence of delirium, or incidence of PONV); and study
design: RCT or quasi-RCT. Observational studies, retrospective
studies, case reports, letters, reviews, and abstracts were excluded.2.3. Data extraction and outcome measurement
The 2 reviewers (JMK and HYK) selected all datasets for this
study. Disagreements were resolved by discussion and consensus.
Authors of potentially relevant studies were contacted for further
information if the relevant data were not published. Among the
primary outcomes, awakening time was deﬁned as the time (in
minutes) from the termination of sedative administration to
awakening. Extubation time was deﬁned as the time (in minutes)
from the termination of sedative administration to extubation.
The LOS in the ICU and hospital were deﬁned as the hours and
the days from admission to discharge. Among the secondary
outcomes, myocardial effects were determined by examining
serum troponin (mg/L) and serum N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) (pg/mL) levels after ICU
admission. The serum creatinine (mg/dL) level on the ﬁrst
postoperative day was used as a measure of the renal effects. The
incidences of delirium and PONVwere recorded as the number of
patients who experienced these effects during the post-sedation
period. If studies had more than 1 volatile or IV sedation arm, the
arms were combined such that there was only 1 volatile and 1
sedation arm.22.4. Quality assessment
Two reviewers assessed the articles and investigated the risk of
bias for RCTs using the Risk of Bias tool from the Cochrane
Collaboration.[40] The 7 different domains were as follows:
random sequence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assessments,
incomplete outcome data, selective reporting, and other bias. The
risk of bias for each trial was reported as “low,” “unclear,” or
“high.” In the allocation concealment domain, we considered the
difﬁculty in ensuring complete blinding of a caregiver when
administering sedation to a patient via anesthetic reﬂectors or IV.
The primary outcomes, such as awakening and extubation times
and LOS in the ICU and hospital, were estimated according to the
robustness of the study protocol. If the trial had objective criteria,
such as a targeted sedation level or plans for stopping sedation
and starting ventilator weaning, the risk of bias was rated as low
despite the lack of blindness. For PONV and delirium outcomes,
we also evaluated whether the method of measurement was
objective. In the selective reporting domain, we evaluated bias
based on protocols from http://www.clinicaltrials.gov and
outcomes that were expressed in the methods. For other bias
domains, we considered the inﬂuence of sponsors. If the trials
received ﬁnancial assistance from a medical instrument or
pharmaceutical company, the risk of bias was rated as “unclear.”
Review Manager software (RevMan; version 5.3) was used to
present the risk of bias.2.5. Data synthesis and statistical analysis
Data that were reported as median and range were changed to
mean and standard deviation.[41] Data that were not reported
numerically in the original articles were extracted from the
ﬁgures. Measurement units were standardized. Troponin I levels
were converted to troponin T levels using a conversion factor of
0.65/2, based on the ratio of the upper limit and previous
literature.[16] Units of serum creatinine levels were converted to
mg/dL. Meta-analyses were performed to calculate the pooled
mean difference (MD) for continuous data or the odds ratio (OR)
for dichotomous data with 95% conﬁdence intervals (95% CIs)
using either a ﬁxed effects or random effects model. Heterogene-
ity was assessed using the Cochrane Q test and I2 statistics.[42]
The ﬁxed effects model was used for meta-analysis unless at least
4 studies were included and the I2 exceeded 50, at which point the
random effects model was used. In addition, subgroup analyses
were performed in primary outcomes showing substantial
heterogeneity to identify the inﬂuence of sedation duration,
patient type, ﬁnancial support, and type of IV agents. Differences
in effect size between subgroups were analyzed with a meta-
regression model. Publication bias was evaluated using the Egger
regression test and a funnel plot.[43] If the outcomes showed
signiﬁcant publication bias, then the trim and ﬁll method was
used for additional analyses. All statistical analyses were
performed using the meta-analysis package for R ver. 3.3.2
(metaphor; Vienna, Austria; http://www.R-project.org).[44]3. Results
3.1. Study selection
A ﬂow chart illustrating the study selection process is shown in
Fig. 1. We retrieved 1532 records in our initial search. After
removing 459 duplicates, we excluded 1023 other records for
the following reasons: non-ICU or nonvolatile sedation studies
Figure 1. Flow diagram depicting the study selection process.
Kim et al. Medicine (2017) 96:49 www.md-journal.com(n=547), pediatric patients (n=242), reviews or meta-analyses
(n=70), case reports, comments, letters, or conference papers
(n=68), abstracts only (n=61), and animal studies (n=35). Of
the 50 potentially eligible studies, we excluded 37 because they
did not meet the PICOS criteria. Ultimately, 13 RCTs published
between November 2004 and May 2017 were included in the
meta-analysis.
3.2. Characteristics of the included studies
Thirteen studies[26–38] were included in the analysis. Two sets of
studies ([27,29] and [30,32]) were assumed to be the same trials
based on their clinical trial numbers (http://www.clinicaltrials.
gov). Because the outcomes overlapped in 2 of these studies,[27,29]
outcomes were extracted from the study with the larger sample
size.[29] Because 1 study[32] represented outcomes of continuous
variables as medians and interquartile ranges without the ﬁrst
and third quartiles, these outcomes were excluded and only
outcomes with categorical variables, such as the incidences of
delirium and PONV, were included in our meta-analysis. Three
studies were performed in mixed medical-surgical ICUs,[26,28,31]
while the remaining 10 studies were performed in surgical ICUs
consisting of only postsurgical patients.[27,29,30,32–38] Of the 10
studies performed in surgical ICUs, 1 study included patients who
underwent major abdominal, vascular, or thoracic surgery,[29]
while the other 9 studies only enrolled patients who underwent
cardiac surgery.[27,30,32–38] All included studies used the
AnaConDa device in the volatile sedation arm; there was no
RCT using the Mirus device. Among the 13 included studies, 9
compared sevoﬂurane with propofol,[27,29,30,32–37] 3 compared
isoﬂurane with midazolam,[26,28,38] and 1 compared sevoﬂurane
with propofol andmidazolam.[31] We did not consider the type of3anesthetics used intraoperatively. The characteristics of the
included studies are summarized in Table 1. The details on the
sedation scales used in the included studies are listed in Table S1,
Supplemental Content, http://links.lww.com/MD/B988.3.3. Quality assessment
The 13 included studies were evaluated using the Risk of Bias tool
(Fig. 2). Although 2 sets of studies were identiﬁed as being the
same trials ([27,29] and [30,32]), the risk of bias in these studies was
assessed independently because the included outcomes did not
coincide. Detailed information on the risk of bias assessment is
presented Table 2.
3.4. Primary outcomes
3.4.1. Awakening time. The 4 studies that examined awakening
time included a total of 181 patients, with 86 in the volatile
sedation arm and 95 in the IV sedation arm.[26,27,31,38] Our
analysis using the random effects model showed that the
awakening time was signiﬁcantly shorter for volatile sedation
than for IV sedation (MD, 80.1minutes; 95% CIs, 134.5 to
25.6; P= .004; I2=95%; Fig. 3). Subgroup analyses were
performed to explore possible sources of heterogeneity. In
subgroup analyses, the pooled effect sizes were smaller in the
short-term (24hours) sedation group[29,38] (MD, 41.7
minutes, 95% CIs, 51.2 to 32.1; P< .001; I2=0%) than
the long-term (>24hours) sedation group[26,31] (MD, 133.1
minutes, 95% CIs, 170.7 to 95.5; P< .001; I2=54%)
(Figure S1, Supplemental Content, http://links.lww.com/MD/
B988). The pooled effect sizes between subgroups were
signiﬁcantly different (P< .001) using meta-regression.
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53.4.2. Extubation time. Although 6 studies presented the
extubation time as an outcome,[26,27,31,32,37,38] 2 studies were
excluded due to ambiguous start time measurements[37] and
different data representation.[32] There were 181 patients (86 in
the volatile sedation arm and 95 in the IV sedation arm) in the 4
included studies.[26,27,31,38] In the pooled analysis using the
random effects model, volatile sedation signiﬁcantly shortened
the extubation time compared with IV sedation (MD, 196.0
minutes; 95% CIs, 305.2 to 86.8; P< .001; I2=90%; Fig. 4).
In subgroup analyses, the short-term (24hours) sedation
group[29,38] showed a smaller effect on extubation time (MD,
108.5minutes, 95%CIs,125.2 to91.9; P< .001; I2=52%)
than the long-term (>24h) sedation group[26,31] (MD, 284.4
minutes, 95% CIs, 388.9 to 179.9; P< .001; I2=54%)
(Figure S2, Supplemental Content, http://links.lww.com/MD/
B988). The pooled effect sizes between subgroups were also
signiﬁcantly different (P= .006) using meta-regression. Addition-
al subgroup analyses according to whether or not the studies
received ﬁnancial support from a medical instrument or
pharmaceutical company (P= .911) or which IV agent was used
(propofol vs midazolam) (P= .542) did not show any signiﬁcant
differences using meta-regression, and heterogeneity remained
high at >80%.
3.4.3. LOS in the ICU and hospital.A total of 658 patients (321
in the volatile sedation arm and 337 in the IV sedation arm) from
8 studies[28,29,31,33,34,36–38] were included in the analysis of LOS
in the ICU. The pooled analysis using the ﬁxed effects model did
not show a signiﬁcant difference between volatile and IV sedation
in terms of LOS in the ICU (MD, 0.9hours; 95% CIs, 3.6 to
1.8; P= .513; I2=0%; Fig. 5). For the analysis of LOS in the
hospital, 465 patients (225 in the volatile sedation arm and 240 in
the IV sedation arm) from 5 studies were identiﬁed.[29,33,34,37,38]
The pooled effect sizes were comparable between both arms using
the ﬁxed effects model (MD, 0.5hours; 95% CIs, 1.0 to 0.0;
P= .059; I2=0%; Fig. 6).
3.5. Secondary outcomes
3.5.1. Myocardial and renal effects. Five studies with a total
464 patients used serum troponin T[30,34,36] or troponin I[33,35]
levels as a marker of cardiac injury. Serum troponin I levels were
converted to troponin T levels according to a predeﬁned formula
(Troponin T=Troponin I
∗
0.65/2). All of the patients in the
eligible studies underwent cardiac surgery and were sedated
with low-dose sevoﬂurane (end-tidal concentration 0.5–1%) or
propofol (1–4mg/kg/h) after admission to the ICU. Because each
trial measured the serum troponin at different time points after
ICU admission, we analyzed the data by dividing them into
time intervals as follows: 0 to 6, 6 to 12, 12 to 24, and 24 to
48hours after ICU admission. The serum troponin levels were
signiﬁcantly lower in the volatile sedation arm than the IV
sedation arm at the 6 to 12, 12 to 24, and 24 to 48-hour intervals,
but not at the 0 to 6-hour time interval (Fig. 7). The effect size was
largest in the 12 to 24-hour time interval (MD,0.27mg/L; 95%
CIs, 0.44 to 0.09; P= .003; I2=73%). Serum NT-proBNP on
the ﬁrst postoperative day was recorded in 3 studies[30,33,35] and
was signiﬁcantly lower in the volatile sedation arm than the IV
sedation arm (MD,711.6pg/mL; 95% CIs, 904.9 to 518.3;
P< .001; I2=90%, Fig. 8).
Renal effects of sedatives were assessed by measuring serum
creatinine levels on the ﬁrst postoperative day. The 5 included
studies[29–31,34,36] consisted of 489 patients with 246 in the
Figure 2. Risk of bias graph (A) and summary (B) of the included studies. + indicates a low risk of bias, indicates a high risk of bias, and? indicates an unclear risk
of bias.
Kim et al. Medicine (2017) 96:49 Medicinesevoﬂurane arm and 243 in the propofol arm. Although no study
showed a signiﬁcant difference, the pooled analysis showed a
lower serum creatinine level in the sevoﬂurane arm compared
with the propofol arm (MD, 0.05mg/dL; 95% CIs, 0.10 to
0.002; P= .043; I2=44%, Fig. 9).
3.5.2. Delirium and PONV. Four studies evaluated the incidence
of delirium by clinician observations[29,31] or patient question-
naires.[28,32] A signiﬁcantly lower incidence of delirium was
identiﬁed in the volatile sedation arm (OR, 0.47; 95% CIs, 0.23–
0.94; P= .033, I2=0%) compared with the IV sedation arm
(Fig. 10). The incidence of PONV from 4 studies,[29,32,34,37]Figure 3. Forest plot of the mean differences and 95% conﬁdence intervals (CIs
analyzed using a random effects model.
6which compared sevoﬂurane sedation with propofol sedation in
postsurgical patients, was comparable between the volatile
and IV sedation arms (OR, 1.58; 95% CIs, 0.97–2.58; P= .068;
I2=0%, Fig. 11).
3.6. Publication bias
Although the number of included studies for each outcome was
small, we evaluated publication bias using the Egger regression
test and a funnel plot. Adjustment using the trim and ﬁll method
was performed for the extubation time and incidence of delirium,
which showed a positive publication bias. The extubation time) for awakening time (in min) in the volatile and IV sedation groups. Data were
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Figure 5. Forest plot of the mean differences and 95% conﬁdence intervals (CIs) for length of stay (in h) in the intensive care unit in the volatile and IV sedation
groups. Data were analyzed using a ﬁxed effects model.
Figure 4. Forest plot of the mean differences and 95% conﬁdence intervals (CIs) for extubation time (in min) in the volatile and IV sedation groups. Data were
analyzed using a random effects model.
Figure 6. Forest plot of the mean differences and 95% conﬁdence intervals (CIs) for length of stay (in d) in the hospital in the volatile and IV sedation groups. Data
were analyzed using a ﬁxed effects model.
Kim et al. Medicine (2017) 96:49 www.md-journal.comafter including 2 imputed studies to improve asymmetry still
showed a signiﬁcant reduction in the volatile sedation arm
compared with the IV sedation arm (MD, 108.5minutes; 95%
CIs, 124.8 to 92.3; P< .001). The incidence of delirium after
including 1 imputed study did not showany difference between the
2 arms (OR, 0.54; 95%CIs, 0.27–1.05;P= .070) after adjustment.94. Discussion
Our systematic review and meta-analysis of 13 RCTs revealed
that sedation in the ICU with volatile anesthetic agents compared
with conventional IV sedatives, such as propofol or midazolam,
shortened the awakening time by 80minutes and the extubation
Figure 7. Forest plot of the mean differences and 95% conﬁdence intervals (CIs) for serum troponin levels (mg/L) at different time points after ICU admission. The
data were analyzed by dividing them into time intervals as follows: (A) 0–6h, (B) 6–12h, (C) 12–24h, and (D) 24–48h after ICU admission. (E) The line represents the
difference in means and the vertical bar represents 95% conﬁdence intervals for serum troponin levels (vertical axis) at different time points after ICU admission
(horizontal axis).
Kim et al. Medicine (2017) 96:49 Medicinetime by 196minutes. Despite these reductions in awakening and
extubation times with volatile sedation, no reductions in the LOS
in the ICU or hospital were noted. Compared with IV sedation,
volatile sedation showed lower serum troponin and NT-proBNP10levels, beginning around 6hours after ICU admission, although
cardiac function was not directly evaluated.
After the introduction of volatile sedation, there have
been several recent meta-analyses in ICU patients[45,46] and
Figure 8. Forest plot of the mean differences and 95% conﬁdence intervals (CIs) for serum N-terminal prohormone of brain natriuretic peptide levels (pg/mL) on the
ﬁrst postoperative day. Data were analyzed using a ﬁxed effects model.
Figure 9. Forest plot of the mean differences and 95% conﬁdence intervals (CIs) for serum creatinine levels (mg/dL) on the ﬁrst postoperative day. Data were
analyzed using a ﬁxed effects model.
Figure 10. Forest plot of the risk ratio and 95% conﬁdence intervals (CIs) for the incidence of delirium in the volatile and IV sedation groups. Data were analyzed
using a ﬁxed effects model.
Figure 11. Forest plot of the risk ratio and 95% conﬁdence intervals (CIs) for the incidence of postoperative nausea and vomiting in the volatile and IV sedation
groups. Data were analyzed using a ﬁxed effects model.
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Kim et al. Medicine (2017) 96:49 Medicinepostcardiac surgical patients. However, these meta-analyses
included volatile sedation using a conventional vaporizer, which
had signiﬁcantly slow anesthetic wash-out times compared with
the new anesthetic reﬂectors using the same fresh gas ﬂow rates;
this is because the conventional vaporizer could not be removed
from the breathing circuit.[48,49] In addition, the time difference of
more than 5 years between studies using conventional vaporizers
versus the new anesthetic reﬂectors might have been inﬂuenced by
changes in the sedation guidelines. Therefore, we selected only
studies that used the new anesthetic reﬂectors. Because no RCT
used the Mirus device, our meta-analysis included only RCTs
using the AnaConDa device.
The results of our pooled analysis, as well as each included
study, showed signiﬁcantly shorter awakening and extubation
times in the volatile sedation arm than in the IV sedation arm,
regardless of whether propofol or midazolam was used as the
conventional IV sedative. The rapid elimination of volatile
anesthetics via pulmonary exhalation, lack of accumulation, and
increased control of the drug concentration by monitoring end-
tidal fractions are likely explanations for these results.[10,11] For
the volatile agents, analgesic effects induced by N-methyl-D-
aspartate antagonist activity[31] may have contributed to opioid-
sparing effects and shorter awakening and extubation times.
However, there was a lack of criteria for controlling pain. In
addition, various types of analgesics such as acetaminophen,
morphine, remifentanil, and sufentanil were used in this study.
Therefore, further evaluations are needed to elucidate opioid-
sparing effects of volatile agents.
Meanwhile, our pooled effect size in extubation time (196
minutes) was larger than was seen in previous meta-analyses,
which showed pooled effect sizes of 52.7minutes[45] and 76
minutes.[47] This result may be explained by the fact that we only
included studies using the AnaConDa device and excluded 2
studies of extubation time fromouranalysisdue toambiguous time
measurements[37] and different data representations.[30] Despite
the more consistent selection of studies, however, substantial
heterogeneity (I2=90%) remained. To identify sources of
heterogeneity, we performed additional subgroup analyses in
awakening and extubation times according to the sedation
duration [short-term (24hours) vs long-term (>24h)], patient
type (cardiac surgical patients vs noncardiac surgical or medical
patients), ﬁnancial support (supported vs unsupported studies
from a medical instrument or pharmaceutical company), and
which IV agent was used (midazolam vs propofol). The subgroup
analyses according to sedation duration and patient type showed
reduced heterogeneity (I2=50–52%), and the MD was greater in
the long-term sedation (> 24h) and noncardiac surgery groups
than the short-term sedation (24hours) and cardiac surgery
groups. Other subgroup analyses according to ﬁnancial support
and IV agents were comparable between the 2 sedation groups.
However, all subgroup analyses should be cautiously interpreted
due to the small number of included studies.
The correlation between the duration of mechanical ventilation
(MV), LOS in the ICU, and complications such as increased
ventilator dependency, ventilator-associated pneumonia, and
ventilator-induced lung injury has been previously estab-
lished.[50,51] A meta-analysis comparing ICU sedatives by
Fraser et al[52] showed that non-benzodiazepine based sedation
shortened the MV duration and LOS in the ICU compared with
benzodiazepine-based sedation. Although volatile sedation
shortened the MV duration in the present study, our meta-
analysis did not indicate that volatile sedation shortened the LOS
in the ICU. Before interpreting the results for LOS, we examined12the length of sedation and MV duration. Here, the mean MV
duration in all of the studies was within 3 days; this was different
from the mean MV duration in the studies examined by Fraser
et al,[52] which ranged from 3.7 to 8.4 days. Relatively short
sedation periods in these studies that we included might be
insufﬁcient to reveal differences in LOS in the ICU. Therefore,
additional studies with longer sedation periods and controlled
conditions should be performed to examine the link between type
of sedation and LOS in the ICU.
The end-organ protective effects of halogenated volatile
agents have also been examined previously by numerous
studies.[15–17,53–57] Among these, the most extensive studies
focused on cardiac effects. Such studies conﬁrmed that volatile
agents reduce myocardial damage when administered immedi-
ately before an ischemic event (pre-conditioning) or during the
early reperfusion period after an ischemic event (post-condition-
ing).[54,58] Several receptors and chemical mediators have been
shown to play roles in the reduction of ischemia/reperfusion
injury in hibernating and stunned tissue.[15] Because the optimal
length of volatile agent administration for maximizing the post-
conditioning effect is unknown, several studies investigated the
cardioprotective effects using volatile agents as sedatives in the
ICU.[30,33–36] Our pooled effect sizes from 5 cardiac surgical
populations were 0.27mg/L in troponin T (at the largest time
interval; 12–24hours after ICU admission) and 711pg/mL in
NT-proBNP. Considering the upper reference limits (0.014mg/L
in troponin T and 300pg/mL in NT-proBNP) for diagnosing
myocardial infarction and heart failure,[59,60] the pooled results
suggest that even a late (postoperative) and subanesthetic dose
(one-third of the dose used for general anesthesia) may have
cardioprotective effects (Fig. 6). However, there were differences
in intraoperative management and postoperative sedation
durations. Unfortunately, we were unable to perform an analysis
to calibrate the sedation duration, as not every study reported the
exact sedation duration. Thus, further studies that can adjust for
sedation duration are needed.
Several previous studies have also reported that volatile agents
are renoprotective.[53,56,61] However, the risk of nephrotoxicity
from inorganic ﬂuoride, which formswhen volatile agents such as
sevoﬂurane are metabolized, is still a concern. Although our
analysis identiﬁed differences in the serum creatinine levels on
the ﬁrst postoperative day, the pooled effect size of 0.05mg/dL
was too small to assess the effect on renal function if signiﬁcant
renal dysfunction was deﬁned as an increase of 0.3mg/dL over
baseline.[62,63] Similarly, whether volatile agents have neuro-
protective effects[55,64] or are neurotoxic and induce cognitive
dysfunction[65,66] remains controversial. There was a difference
in the incidence of delirium between the volatile and IV sedation
arms; however, after adjusting for publication bias, both arms
were comparable. Furthermore, delirium, which was used as a
marker of cognitive dysfunction, was not measured using
currently recommended tools (i.e., the Confusion Assessment
Method for ICU or the Intensive Care Delirium Screening
Checklist). Therefore, the data regarding the effects of sedative
agents on the kidney and brain should be interpreted with
caution.
One of the major concerns of using volatile agents is
PONV.[18,67,68] When administering general anesthesia, volatile
agents are known to be a potent risk factor of PONV.[19] In our
analysis, the pooled OR of PONV did not show a signiﬁcant
difference between the volatile and IV sedation arms. However,
the interpretation was limited due to variance among studies in
terms of adjuvant opioid and anti-emetic usage.
[2] Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the
Kim et al. Medicine (2017) 96:49 www.md-journal.comThe present study has several limitations. First, the number of
included studies and sample sizes were small and the study
durations were short. The largest study included only 141
subjects, and the mean sedation duration in all of the studies was
less than 3 days. Thus, several outcomes may have been
underpowered. Second, none of the included studies, except for
one,[33] were double-blind; it is likely that this lack of blindness
affected the observed ﬁndings. Third, these studies had multiple
heterogeneities, including the group of patients examined
(medical or surgical, cardiac or noncardiac surgical patients),
intraoperative anesthesia (volatile anesthesia or total IV
anesthesia), patient management (different methods of assessing
sedation), and outcome measurement (different time points for
measuring outcomes). These heterogeneities might have inﬂu-
enced outcomes by introducing many potential confounders.
Fourth, all studies included were conducted in Europe except 1
Egyptian study.[38] Therefore, it is uncertain whether interconti-
nental differences in sedation practices might have affected
outcomes. Fifth, we used laboratory values to evaluate end-organ
protective effects and did not to directly measure organ function.
Finally, we could not analyze other important factors such as
cost-effectiveness, hemodynamic stability, or the effects of
increased respiratory dead space and work of breathing.
Despite several limiting factors, our studyprovides the following
new knowledge. First, volatile sedation using the only new
anesthetic reﬂector had more reduction in awakening and
extubation times than previous meta-analyses,[45–47] including
studies using conventional ventilator and new anesthetic reﬂector
together. In addition, the effect size was greater in long-term
sedation (>24hours) than short-term sedation (24hours).
Second, subanesthetic dose (one-third of the dose used for general
anesthesia) of volatile sedation administered after cardiac surgery
might have cardioprotective effects. Third, major concerns about
volatile anesthetics (nephrotoxicity, nausea, and vomiting) were
not proven at the sedation dose used in the present study.
A strengthofourmeta-analysiswas thatweonly includedRCTs;
before-and-after and retrospective studies were excluded to
minimize biases such as drug hangover effects. The fact that
we only included studies where the AnaConDa device was
usedalso reducedbias. To the best of ourknowledge, this is theﬁrst
meta-analysis to compare volatile sedation via the AnaConDa
device with IV sedation in the ICU. Our results demonstrate that
volatile sedation supports the current sedation practice emphasiz-
ing daily awakening and early extubation.[2] Especially, ICU
patients requiring long-term sedation may beneﬁt from volatile
sedation due to rapid elimination of volatile anesthetics. In
addition, postsurgical sedation after cardiac surgery may beneﬁt
from volatile sedation in term of myocardial protection.
In conclusion, the present meta-analysis found that volatile
sedatives administered through the AnaConDa device in the ICU
reduced awakening and extubation times compared with IV
sedatives. Moreover, subanesthetic doses of volatile sedation
administered after cardiac surgery might have cardioprotective
effects. Given the technological advancements in volatile vaporizers,
it is possible that volatile sedation will become the new standard of
care in ICU sedation. However, because the included studies were
small with high heterogeneity, additional large, high-quality
prospective clinical trials are needed to validate these ﬁndings.
References
[1] Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for
the sustained use of sedatives and analgesics in the critically ill adult.
Crit Care Med 2002;30:119–41.13management of pain, agitation, and delirium in adult patients in the
intensive care unit. Crit Care Med 2013;41:263–306.
[3] SydowM, Neumann P. Sedation for the critically ill. Intensive Care Med
1999;25:634–6.
[4] Ahmed S, Murugan R. Dexmedetomidine use in the ICU: are we there
yet? Crit Care 2013;17:320.
[5] Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs
midazolam for sedation of critically ill patients: a randomized trial.
JAMA 2009;301:489–99.
[6] Tan JA, Ho KM. Use of dexmedetomidine as a sedative and analgesic
agent in critically ill adult patients: a meta-analysis. Intensive Care Med
2010;36:926–39.
[7] Holliday SF, Kane-Gill SL, Empey PE, et al. Interpatient variability
in dexmedetomidine response: a survey of the literature. Sci World J
2014;2014:805013.
[8] Page VJ, McAuley DF. Sedation/drugs used in intensive care sedation.
Curr Opin Anaesthesiol 2015;28:139–44.
[9] Mirrakhimov AE, Voore P, Halytskyy O, et al. Propofol infusion
syndrome in adults: a clinical update. Crit Care Res Pract 2015;2015:
260385.
[10] Whalen FX, Bacon DR, Smith HM. Inhaled anesthetics: an historical
overview. Best Pract Res Clin Anaesthesiol 2005;19:323–30.
[11] Preckel B, Bolten J. Pharmacology of modern volatile anaesthetics. Best
Pract Res Clin Anaesthesiol 2005;19:331–48.
[12] Patel SS, Goa KL. Sevoﬂurane. A review of its pharmacodynamic and
pharmacokinetic properties and its clinical use in general anaesthesia.
Drugs 1996;51:658–700.
[13] Orriach JL, Aliaga MR, Ortega MG, et al. Sevoﬂurane in intraoperative
and postoperative cardiac surgery patients. Our experience in intensive
care unit with sevoﬂurane sedation. Curr PharmDes 2013;19:3996–4002.
[14] Guarracino F, Landoni G, Tritapepe L, et al. Myocardial damage
prevented by volatile anesthetics: a multicenter randomized controlled
study. J Cardiothorac Vasc Anesth 2006;20:477–83.
[15] Landoni G, Fochi O, Tritapepe L, et al. Cardiac protection by volatile
anesthetics. A review. Minerva Anestesiol 2009;75:269–73.
[16] Symons JA, Myles PS. Myocardial protection with volatile anaesthetic
agents during coronary artery bypass surgery: a meta-analysis. Br J
Anaesth 2006;97:127–36.
[17] Burchell SR, Dixon BJ, Tang J, et al. Isoﬂurane provides neuroprotection
in neonatal hypoxic ischemic brain injury. J Investig Med 2013;61:
1078–83.
[18] Apfel CC, Kranke P, Eberhart LH, et al. Comparison of predictive
models for postoperative nausea and vomiting. Br J Anaesth 2002;
88:234–40.
[19] Apfel CC, Kranke P, KatzMH, et al. Volatile anaestheticsmay be themain
cause of early but not delayed postoperative vomiting: a randomized
controlled trial of factorial design. Br J Anaesth 2002;88:659–68.
[20] Apfel CC, Stoecklein K, Lipfert P. PONV: a problem of inhalational
anaesthesia? Best Pract Res Clin Anaesthesiol 2005;19:485–500.
[21] Welborn LG, Hannallah RS, Norden JM, et al. Comparison of emergence
and recovery characteristics of sevoﬂurane, desﬂurane, and halothane in
pediatric ambulatory patients. Anesth Analg 1996;83:917–20.
[22] Cousins MJ, Mazze RI. Methoxyﬂurane nephrotoxicity. A study of dose
response in man. JAMA 1973;225:1611–6.
[23] Meiser A, Laubenthal H. Inhalational anaesthetics in the ICU: theory and
practice of inhalational sedation in the ICU, economics, risk-beneﬁt. Best
Pract Res Clin Anaesthesiol 2005;19:523–38.
[24] Enlund M, Wiklund L, Lambert H. A new device to reduce the
consumption of a halogenated anaesthetic agent. Anaesthesia 2001;
56:429–32.
[25] Bomberg H, Glas M, Groesdonk VH, et al. A novel device for target
controlled administration and reﬂection of desﬂurane: the Mirus (TM).
Anaesthesia 2014;69:1241–50.
[26] Sackey PV, Martling CR, Granath F, et al. Prolonged isoﬂurane sedation
of intensive care unit patients with the Anesthetic Conserving Device.
Crit Care Med 2004;32:2241–6.
[27] Rohm KD, Wolf MW, Schollhorn T, et al. Short-term sevoﬂurane
sedation using the Anaesthetic Conserving Device after cardiothoracic
surgery. Intensive Care Med 2008;34:1683–9.
[28] Sackey PV, Martling CR, Carlsward C, et al. Short- and long-term
follow-up of intensive care unit patients after sedation with isoﬂurane
and midazolam: a pilot study. Crit Care Med 2008;36:801–6.
[29] Rohm KD, Mengistu A, Boldt J, et al. Renal integrity in sevoﬂurane
sedation in the intensive care unit with the anesthetic-conserving device: a
comparison with intravenous propofol sedation. Anesth Analg 2009;
108:1848–54.
[30] Hellstrom J, Owall A, Bergstrom J, et al. Cardiac outcome after [50] Kress JP, Pohlman AS, O’Connor MF, et al. Daily interruption of
Kim et al. Medicine (2017) 96:49 Medicinesevoﬂurane versus propofol sedation following coronary bypass surgery:
a pilot study. Acta Anaesthesiol Scand 2011;55:460–7.
[31] Mesnil M, Capdevila X, Bringuier S, et al. Long-term sedation in
intensive care unit: a randomized comparison between inhaled
sevoﬂurane and intravenous propofol or midazolam. Intensive Care
Med 2011;37:933–41.
[32] Hellstrom J, Owall A, Sackey PV. Wake-up times following sedation
with sevoﬂurane versus propofol after cardiac surgery. Scand Cardiovasc
J 2012;46:262–8.
[33] Soro M, Gallego L, Silva V, et al. Cardioprotective effect of sevoﬂurane
and propofol during anaesthesia and the postoperative period in
coronary bypass graft surgery: a double-blind randomised study. Eur J
Anaesthesiol 2012;29:561–9.
[34] Steurer MP, Steurer MA, Baulig W, et al. Late pharmacologic
conditioning with volatile anesthetics after cardiac surgery. Crit Care
2012;16:R191.
[35] Guerrero Orriach JL, Galan Ortega M, Ramirez Aliaga M, et al.
Prolonged sevoﬂurane administration in the off-pump coronary artery
bypass graft surgery: beneﬁcial effects. J Crit Care 2013;28:879.e13–8.
[36] Marcos-Vidal JM, Gonzalez R, Garcia C, et al. Sedation with sevoﬂurane
in postoperative cardiac surgery: inﬂuence on troponin T and creatinine
values. Heart Lung Vessel 2014;6:33–42.
[37] Jerath A, Beattie SW, Chandy T, et al. Volatile-based short-term sedation
in cardiac surgical patients: a prospective randomized controlled trial.
Crit Care Med 2015;43:1062–9.
[38] HanafyM. Clinical evaluation of inhalation sedation following coronary
artery bypass grafting. Eg J Anaesth 2005;21:237–42.
[39] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration. J Clin Epidemiol
2009;62:e1–34.
[40] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collabo-
ration’s tool for assessing risk of bias in randomised trials. BMJ
2011;343:d5928.
[41] Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard
deviation from the sample size, median, range and/or interquartile range.
BMC Med Res Methodol 2014;14:135.
[42] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in
meta-analyses. BMJ 2003;327:557–60.
[43] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997;315:629–34.
[44] Viechtbauer W. Conducting meta-analyses in R with the metafor
package. J Stat Software 2010;36:1–48.
[45] Jerath A, Panckhurst J, Parotto M, et al. Safety and efﬁcacy of volatile
anesthetic agents compared with standard intravenous midazolam/
propofol sedation in ventilated critical care patients: a meta-analysis and
systematic review of prospective trials. Anesth Analg 2017;124:1190–9.
[46] Landoni G, Pasin L, Cabrini L, et al. Volatile agents in medical and
surgical intensive care units: a meta-analysis of randomized clinical trials.
J Cardiothorac Vasc Anesth 2016;30:1005–14.
[47] Spence J, Belley-Cote E, Ma HK, et al. Efﬁcacy and safety of inhaled
anaesthetic for postoperative sedation during mechanical ventilation in
adult cardiac surgery patients: a systematic review and meta-analysis.
Br J Anaesth 2017;118:658–69.
[48] Tempia A, Olivei MC, Calza E, et al. The anesthetic conserving device
compared with conventional circle system used under different ﬂow
conditions for inhaled anesthesia. Anesth Analg 2003;96:1056–61.
table of contents.
[49] Nishiyama T. Saving sevoﬂurane and hastening emergence from
anaesthesia using an anaesthetic-conserving device. Eur J Anaesthesiol
2009;26:35–8.14sedative infusions in critically ill patients undergoing mechanical
ventilation. N Engl J Med 2000;342:1471–7.
[51] Lonardo NW, Mone MC, Nirula R, et al. Propofol is associated with
favorable outcomes compared with benzodiazepines in ventilated
intensive care unit patients. Am J Respir Crit Care Med 2014;189:
1383–94.
[52] Fraser GL, Devlin JW, Worby CP, et al. Benzodiazepine versus
nonbenzodiazepine-based sedation for mechanically ventilated, critically
ill adults: a systematic review and meta-analysis of randomized trials.
Crit Care Med 2013;41:S30–8.
[53] Fukazawa K, Lee HT. Volatile anesthetics and AKI: risks, mechanisms,
and a potential therapeutic window. J Am Soc Nephrol 2014;25:
884–92.
[54] De Hert SG, Turani F, Mathur S, et al. Cardioprotection with volatile
anesthetics: mechanisms and clinical implications. Anesth Analg
2005;100:1584–93.
[55] Zhao P, Peng L, Li L, et al. Isoﬂurane preconditioning improves long-
term neurologic outcome after hypoxic-ischemic brain injury in neonatal
rats. Anesthesiology 2007;107:963–70.
[56] Kong HY, Zhu SM, Wang LQ, et al. Sevoﬂurane protects against acute
kidney injury in a small-size liver transplantation model. Am J Nephrol
2010;32:347–55.
[57] De Conno E, Steurer MP, Wittlinger M, et al. Anesthetic-induced
improvement of the inﬂammatory response to one-lung ventilation.
Anesthesiology 2009;110:1316–26.
[58] Pagel PS. Postconditioning by volatile anesthetics: salvaging ischemic
myocardium at reperfusion by activation of prosurvival signaling.
J Cardiothorac Vasc Anesth 2008;22:753–65.
[59] Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing
for diagnosis and short-term prognosis in acute destabilized heart failure:
an international pooled analysis of 1256 patients. The International
Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330–7.
[60] Kimenai DM, Henry RM, van der Kallen CJ, et al. Direct comparison
of clinical decision limits for cardiac troponin T and I. Heart 2016;
102:610–6.
[61] Cai J, Xu R, Yu X, et al. Volatile anesthetics in preventing acute kidney
injury after cardiac surgery: a systematic review and meta-analysis.
J Thorac Cardiovasc Surg 2014;148:3127–36.
[62] Grynberg K, Polkinghorne KR, Ford S, et al. Early serum creatinine
accurately predicts acute kidney injury post cardiac surgery. BMC
Nephrol 2017;18:93.
[63] Karkouti K, Rao V, Chan CT, et al. Early rise in postoperative creatinine
for identiﬁcation of acute kidney injury after cardiac surgery. Can J
Anaesth 2017;64:801–9.
[64] McAuliffe JJ, Joseph B, Vorhees CV. Isoﬂurane-delayed preconditioning
reduces immediate mortality and improves striatal function in adult mice
after neonatal hypoxia-ischemia. Anesth Analg 2007;104:1066–77.
tables of contents.
[65] Acharya NK, Goldwaser EL, Forsberg MM, et al. Sevoﬂurane and
isoﬂurane induce structural changes in brain vascular endothelial cells
and increase blood-brain barrier permeability: possible link to
postoperative delirium and cognitive decline. Brain Res 2015;1620:
29–41.
[66] Yang CW, Fuh JL. Exposure to general anesthesia and the risk of
dementia. J Pain Res 2015;8:711–8.
[67] Chui J, Mariappan R, Mehta J, et al. Comparison of propofol and
volatile agents for maintenance of anesthesia during elective craniotomy
procedures: systematic review and meta-analysis. Can J Anaesth
2014;61:347–56.
[68] Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth
Analg 2006;102:1884–98.
